Murrangatin
Catalog No: CFN98604
Murrangatin may be a valuable anti-tumor-promoting agent, it
can significantly inhibit Epstein–Barr virus early antigen (EBV–EA) activation, and preserve the high viability of Raji cells, it also exhibits cytotoxicity against cholangiocarcinoma cell line, KKU-100. Murrangatin exhibits antibacterial activity against P. gingivalis (ATCC 33277). Murrangatin also shows soluble epoxide hydrolase inhibitory activity with IC50 values 13.9±6.5uM. Murrangatin and murracarpin may be a new backbone for developing inhibitors of cyclooxygenase 2, they show chondroprotective activity by downregulation of interleukin-1β, tumor necrosis factorα, prostaglandins E2,and matrix metalloproteinases -13, and both of them may be a new backbone for developing inhibitors of cyclooxygenase 2.
Anethole
Catalog No: CFN98550
Anethole has antispasmodic, anti-inflammatory, cardiovascular, and gastroprotective effects. Anethole can act as the CXCR4 antagonist and as the PTEN activator which resulted to PI3K/AKT-mediated inhibition of the metastatic prostate cancer progressions. Anethole may have a potent inhibitory effect on PD through suppression of pro-inflammatory molecules, it could be a novel therapeutic strategy for Periodontitis. Anethole blocks neuronal excitability,and induces the blockade of neuromuscular transmission. trans-Anethole has insecticidal activity to adult fruit flies of Ceratitis capitata, Bactrocera dorsalis, and Bactrocera cucurbitae.
Cordycepin
Catalog No: CFN98566
Cordycepin possesses immunological stimulating,anti-hyperglycemia, anti-cancer, neuroprotective, antifungal, antibacterial, anti-inflammatory, anti-virus and anti-infection activities. Cordycepin has inhibitory effects on osteoclast differentiation in vitro and that it suppresses inflammatory bone loss in vivo. Cordycepin inhibited the production of NO production by down-regulation of iNOS and COX-2 gene expression via the suppression of NF-κB activation, Akt and p38 phosphorylation, suppressed HMGA2, Twist1 and ZEB1-dependent melanoma invasion and metastasis by targeting miR-33b.